Novo Nordisk’s Latest Clinical Result Is Sending the Stock Plunging. Here’s What Investors Need to Know.

Novo Nordisk (NYSE: NVO) is a Danish pharmaceutical company that’s been around for about a century. It specializes in developing medications for metabolic diseases, such as diabetes and obesity treatment. Most of us have probably heard of their primary products, which include Ozempic and Wegovy. Both of these treatments contain an active ingredient called semaglutide, a so-called GLP-1 drug. Essentially, semaglutide mimics the natural hormone in our bodies that helps control blood sugar and reduces appetite, resulting in weight loss.What sets Novo Nordisk apart is its focus on metabolic diseases- something it’s done for over 100 years. However, the company recently released a particular clinical trial that made investors concerned.Image source: Getty Images.Continue readinghttps://www.fool.com/investing/2025/12/01/novo-nordisks-latest-clinical-result-is-sending-th/